Agoracom Blog Home

Posts Tagged ‘CSE’

VIDEO: Transcanna $TCAN.ca Revenue Run Rate Of $24M Will Increase To $90M When 196,000 Sq Ft Facility Comes Online In 2021

Posted by AGORACOM-JC at 4:04 PM on Wednesday, June 3rd, 2020
tcan-square
  • $2M CAD Revenue April 2020
  • $24.6M CAD Revenue Run Rate solely from TransCanna test facility
  • $90M Annual Revenue expected from first full year upon completion of 196,000 Sq Ft Daly facility Q3 2021
  • Daly facility will be one of the largest cannabis facilities in California
  • Recently acquired two California companies,
    • High-end award winning edible producer Soldaze
    • Premium indoor cultivator and distributer Lyfted Farms
  • Lyfted Farms products sold in select Cookies Locations – The most recognizable name in high-end Cannabis.
  • 2019 California Cannabis sales over $3B, industry currently fragmented
  • Direct to dispensary model, cutting out the middleman

Datametrex $DM.ca Reports Government Clearance To Fulfill Its First #COVID19 Test Kit Order

Posted by AGORACOM-JC at 2:17 PM on Wednesday, June 3rd, 2020
  • Announced that its purchaser has received Government clearance to fulfill the purchase order for COVID-19 test kits for its client, a mining company operational in Mali, West Africa
  • Under the terms of the PO, Datametrex will sell to the purchaser an initial 10,000 units of the iONEBIO Inc. iLAMP Novel-CoV19 Detection Kit; 10,000 3 mL Universal Transport Medium (UTM®) Sterile Swabs with 16x100mm Skirted Tubes with Plastic Red Capture Caps, and 1 Real-Time PCR Detection System machine to analyze the samples
  • The total gross sales amount is approximately $500,000 CDN, excluding shipping

TORONTO, June 03, 2020 – Datametrex AI Limited (the “Company” or “Datametrex“) (TSXV: DM, FSE: D4G, OTC: DTMXF) is pleased to announce that its purchaser has received Government clearance to fulfill the purchase order (the “PO”) for COVID-19 test kits for its client, a mining company operational in Mali, West Africa.

Under the terms of the PO, Datametrex will sell to the purchaser an initial 10,000 units of the iONEBIO Inc. iLAMP Novel-CoV19 Detection Kit; 10,000 3 mL Universal Transport Medium (UTM®) Sterile Swabs with 16x100mm Skirted Tubes with Plastic Red Capture Caps, and 1 Real-Time PCR Detection System machine to analyze the samples. The iONEBIO test kits provide results within approximately 15 to 20 minutes with 99.9% accuracy. Each kit contains 288 individual tests, all of which can be completed in one hour.

The total gross sales amount is approximately $500,000 CDN, excluding shipping. The Company has secured all testing kits, swabs, tubes and the PCR machine from the manufacturer required to fulfill the order. Datametrex anticipates that it will have little or no upfront costs associated with the sale of these test kits.

With the Government clearance, the Company is in process of organizing shipping. All of the items will be shipped directly from manufacturers to the purchaser at their operating site in West Africa. Security clearance backlogs continue to streamline as Governments align with the World Health Organization’s remarks on the importance of testing. Governments have urged mining companies to implement testing and screening their workforce to properly fight the virus in order to avoid further closures.

“The opportunity to use advanced COVID-19 testing kits from our partners in Korea to support the diagnostic potential for populations provides an exciting opportunity for countries during this pandemic and the African continent,” says Marshall Gunter, CEO of the Company. “Datametrex is honored to be assisting in the health and welfare of mine employees and local contractors.”

According to Africa Centres for Disease Control and Prevention (the “Africa CDC”), there are over 150,000 cases of COVID-19 throughout Africa and with this, Researchers at the African Center of Excellence for Genomics of Infectious Diseases (the “ACEGID”) and other research and public health partners, have announced to implement a Sentinel Project (the “Sentinel”) serveilance protocol for an early warning system in Africa. The Sentinel is the first of eight new projects selected, and it has three pillars: (1) detect, (2) connect and (3) empower. And in the third pillar, the project will empower public health experts by training thousands of healthcare professionals to use the Sentinel tools and deploy the diagnostic technologies for population-level COVID-19 testing, building on previous experiences of ACEGID and the Broad Institute in training over 900 individuals from around the world.

Datametrex’s mission is to provide tools that support companies in fulfilling their operational Health and Safety goals with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, the Company provides progressive solutions to support the supply chain.

About Datametrex

Datametrex AI Limited is a technology focused company with exposure to Artificial Intelligence and Machine Learning through its wholly owned subsidiary, Nexalogy (www.nexalogy.com).

Additional information on Datametrex is available at www.datametrex.com

For further information, please contact:

Marshall Gunter – CEO
Phone: (514) 295-2300
Email: [email protected]

Neither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws.  All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

Nickel supply concerns for #EV use heighten – SPONSOR Tartisan #Nickel $TN.ca – $ROX.ca $FF.ca $EDG.ca $AGL.ca $ANZ.ca

Posted by AGORACOM-JC at 10:53 AM on Wednesday, June 3rd, 2020

SPONSOR: Tartisan Nickel (TN:CSE)  Kenbridge Property has a measured and indicated resource of 7.14 million tonnes at 0.62% nickel, 0.33% copper. Tartisan also has interests in Peru, including a 20 percent equity stake in Eloro Resources and 2 percent NSR in their La Victoria property. Click her for more information

Tc logo in black

Nickel supply concerns for EV use heighten

  • Concerns over the availability of nickel for the battery sector increase from 2022, when electric vehicle (EV) growth picks up again after a period of weak consumer confidence caused by Covid-19
  • About 44% of respondents to a poll at the end of the webinar said nickel was the battery raw material with which they were most concerned about supply sufficiency between 2022 and 2025

By: Charlotte Radford

Concerns over the availability of nickel for the battery sector increase from 2022, when electric vehicle (EV) growth picks up again after a period of weak consumer confidence caused by Covid-19, according to a poll conducted during a Fastmarkets webinar. About 44% of respondents to a poll at the end of the webinar said nickel was the battery raw material with which they were most concerned about supply sufficiency between 2022 and 2025. In contrast, 16% of respondents said nickel was their primary concern in terms of supply disruption or insufficiency while Covid-19 plays out.

“Given the growth we see in EVs and the change in battery chemistries, it’s going to be very hard for nickel producers to keep up with strong forecast CAGR [compound annual growth rate] in the EV market,” Will Adams, Fastmarkets’ head of battery raw materials research, said during the webinar.

Battery chemistries are shifting in favor of high-nickel chemistries, which, subject to the required technological developments, provide greater driving ranges and reduce the need for cobalt per cell.

“The transition to nickel-rich batteries is going be a significant factor for nickel demand growth on top of going into a period of EVs becoming more mainstream, and on top of that, driving ranges increasing, which is going to require larger battery packs. So on three counts, nickel is a winner,” Adams said.

But in the near-term, the requirement for the class 1 nickel that is suitable for battery applications will be felt less acutely, and existing nickel stocks can provide a buffer.

Covid-19 and the economic downturn and uncertainty it has triggered is expected to cause weaker consumer confidence, which will negatively hit EV order books in the short term.

About 79% of respondents to Fastmarkets’ poll said Covid-19 would cause EV adoption to pick up at a slower pace than anticipated, or that there would be a short delay to growth before picking up again and following its previous growth trajectory.

“There will be a slower uptake in EVs, so that does mean demand for nickel in the short term might not be so great, and there might not be such a drawdown on stocks. But the other side of the equation and the longer-term issue is that these low prices are not providing the incentive to invest in the new production of class 1 nickel,” Adams said.

The three-month nickel price on the London Metal Exchange closed at $12,192 per tonne on Friday May 29, down from highs of $18,475 per tonne last September.

Investment has already started in some high-pressure acid leaching (HPAL) projects – which produce class 1 nickel from laterite ore – such as the Tsingshan Group’s joint venture in Indonesia. But more such investments will be required even while nickel prices are low in order to avoid a class 1 nickel shortage when EV usage picks up, Adams said during the webinar.
HPAL projects have a “checkered history,” in terms of their realized capacity and budgetary overruns, Adams added.

“We wait to see if these new HPAL ops come onstream in a timely manner, because that is what the nickel and EV market is going to need – these new HPAL operations, and more of them,” he said.  

Source: https://www.metalbulletin.com/Article/3934923/WEBINAR-Nickel-supply-concerns-for-EV-use-heighten-from-2022-poll.html

TransCanna $TCAN.ca and KeyPLex Collobrate on Innovative Suite of Agro Products to Boost Yield, Treat Plant Pests and Disease $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 7:14 AM on Wednesday, June 3rd, 2020
tcan-square
  • Entered into a Memorandum of Understanding with major agriculture firm KeyPlex, to create and market high quality bio-pesticides, bio-fungicides, and fertilizers with micronutrients specifically created for the cannabis industry
  • Marks the first time a line of bio-controls and specifically formulated fertilizers designed to increase plant vigor during each stage of the life cycle, will be created for the unique needs of cannabis and hemp crops.

Vancouver, British Columbia–(June 3, 2020) – TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) (“TransCanna” or the “Company”) is pleased to announce that it has entered into a Memorandum of Understanding (“MOU”) with major agriculture firm KeyPlex, to create and market high quality bio-pesticides, bio-fungicides, and fertilizers with micronutrients specifically created for the cannabis industry.

The MOU between the global agricultural powerhouse and Lyfted Farms (a TransCanna subsidiary) marks the first time a line of bio-controls and specifically formulated fertilizers designed to increase plant vigor during each stage of the life cycle, will be created for the unique needs of cannabis and hemp crops. In addition, the all-natural, product lines co-branded by the companies meet the standards required to pass stringent testing in order to be compliant in the highly competitive California cannabis space.

Improving soil and plant health via comprehensive nutritional inputs and biostimulants that make nutrient uptake more effective for cannabis plants has several benefits, including increased yields and disease resistance, and improved pest resistance, which can lead to higher profit margins. In addition, healthier soil requires less water, leading to more sustainable water use and lowered associated costs.

“No one has ever created a similar product range targeting the unique needs of cannabis growers before, so we are pleased to offer a portfolio that will benefit growers and sustainable growing practices in addition to cannabis consumers via high quality and all-natural products,” says Bob Blink, TransCanna CEO. “We are pleased to be working with one of the most respected and largest agriculture brands sharing the same values that we do for sustainable agriculture practices to promote the progressiveness and longevity of our industry.”

“This partnership with KeyPlex,” adds Blink, “to offer cutting edge technology reflects our overall strategy to be innovators in the Cannabis space and to live up to the Lyfted Farms motto of ‘a higher standard of growing.'”

In addition, the products offered through this have no pre-harvest interval, zero worker re-entry restrictions, and have no residual testing limitations.

KeyPlex is a recognized giant in the agriculture industry and global market leader in plant pest and disease control and nutrient input programs. The company was established in 1980 and specializes in sustainable, environmentally friendly, botanically based products that are OMRI certified, EPA exempt, and approved for use in California on all cannabis and hemp varieties. KeyPlex products are currently sold across North America, South America and Europe.

“Lyfted Farms was selected to be our sole partner in this exciting new venture because of its reputation for cultivation expertise and the noted quality of its cannabis flower,” said Gerald O’Connor, CEO of KeyPlex. “We share a passion for innovating and for pushing the standards of quality to meet the needs of producers and with end user safety in mind.”

The first two product offerings are in final-phase development and include a broad-spectrum fungicide and a plant-based insecticide that have demonstrated remarkable effectiveness in repeated crop cycles conducted at Lyfted Farms test facility sites in Modesto, CA.

For more information on this MOU and other TransCanna news please visit us our Agoracom investor community:

https://agoracom.com/ir/TranscannaHoldings/forums/discussion/topics/741323-interview-will-be-live-on-wednesday-june-2nd-at-4pm-est/messages/2268937#message

About TransCanna Holdings Inc.

TransCanna Holdings Inc. is a California based, Canadian listed company building Cannabis-focused brands for the California lifestyle, through its wholly-owned California subsidiaries.

For further information, please visit the Company’s website at www.transcanna.com or email the Company at [email protected].

On behalf of the Board of Directors
Bob Blink, CEO
604-349-3011

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

North Bud Farms $NBUD.ca Provides Corporate Update $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 8:49 PM on Tuesday, June 2nd, 2020
  • Signed a definitive agreement to sell all the shares of its U.S. subsidiary, Bonfire Brands USA, Inc.
  • Under the terms of the transaction, the acquiring party is responsible for and guarantees all of BBUSA’s past and future liabilities and capital requirements, including all of the outstanding intercompany debts owed to NORTHBUD up to a maximum of CDN$2 million
  • The acquiror will retain rights to the name “Bonfire Brands” and the Company will no longer proceed with the change of name and symbol that was approved at the last shareholder meeting

TORONTO, June 02, 2020 — North Bud Farms Inc. (CSE: NBUD) (OTCQB: NOBDF) (“NORTHBUD” or the “Company“) provides shareholders with the following corporate update:

U.S. Operations

The Company is pleased to announce that it has signed a definitive agreement to sell all the shares of its U.S. subsidiary, Bonfire Brands USA, Inc. (“BBUSA”), to an entity controlled by Mr. Justin Braune, the President of BBUSA.  The transaction constitutes a related-party transaction as defined in Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The transaction is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as the fair market value of the shares of BBUSA sold to the acquiror does not exceed 25% of the Company’s market capitalization.  This determination is based upon the fact that the value of the net assets of BBUSA is negligible as the assets acquired were, and continue to be, highly leveraged.  In light of the current market conditions, it is no longer economically viable for the Company to continue to try to sustain and develop these assets.

Under the terms of the transaction, the acquiring party is responsible for and guarantees all of BBUSA’s past and future liabilities and capital requirements, including all of the outstanding intercompany debts owed to NORTHBUD up to a maximum of CDN$2 million.  The acquiror will retain rights to the name “Bonfire Brands” and the Company will no longer proceed with the change of name and symbol that was approved at the last shareholder meeting. 

“We are pleased with the successful completion of this deal to divest our U.S. holdings as it will significantly improve the Company’s balance sheet and available cash flow, a key Company objective in light of the difficult economic climate brought on by Covid-19,” said Ryan Brown, NORTHBUD’s Executive Chairman and Interim CEO.  “The structure of this transaction represents the achievement of the Company’s previously-announced plan to remove its direct exposure to the U.S. cannabis sector in order to eliminate the increasing administrative and capital costs associated with such holdings.”

Failure-to-File Cease Trade Order Issued
The following is an update on the previously announced management cease trade order (the “MCTO“) issued by the Ontario Securities Commission on March 31, 2020.  The MCTO was issued in connection with the delay by the Company in filing its annual financial statements, management’s discussion and analysis and related officer certifications for the financial year ended November 30, 2019 (collectively, the “Required Filings“) before the prescribed deadline of March 30, 2020.  

Sequence of Events
As previously disclosed, the Company completed two material U.S.-based acquisitions in November 2019, weeks prior to its year-end, thus obliging the Company to include purchase price accounting and post-acquisition activity for both acquired companies into its consolidated financial statements for the financial year ended November 30, 2019.

The Company took decisive steps to augment its capabilities to manage and report on its expanded operations including the appointment of advisors, valuation and taxation experts to assist with the year-end reporting and audit requirements; the appointments of Sean Homuth as CEO in December 2019, Adam Shapero as General Counsel in January 2020, and Jeffrey Stoss as CFO in February 2020; and, the addition of Jennifer Ross-Carriere and Lisa Mayhew as Directors in December 2019 and February 2020 respectively. Unfortunately, Sean Homuth had to take a medical leave of absence from the Company on April 28, 2020, which resulted in some delays to the progress of the year-end audit as he was interim CFO for the Company around the time of the U.S. acquisitions.

Due primarily to the inability of management, and its advisors and auditors to travel to the U.S. to conduct onsite field work, and due to ongoing travel and work restrictions in both Canada and the U.S. imposed by the impact of COVID-19 and the additional audit and reporting work related to the Company’s stated intention to divest of its U.S. operations as announced May 6, 2020, the Company could not complete and file the Required Filings for the year-ended November 30, 2019 and the quarter-ended February 29, 2020 before the end of the May 31, 2020 deadline contemplated by the MCTO.  The Company, its advisors and its independent auditor, are continuing to work diligently to complete the necessary work and the Company intends to make the Required Filings as soon as possible.

In connection with this delay, on June 2, 2020 the Ontario Securities Commission (“OSC“) issued a failure-to-file cease trade order (“FFCTO“) against the Company.

The FFCTO will affect trading in all securities of the Company in Canada and will remain in effect until such time as the Company has made the Required Filings.  This has resulted in a halt in trading of the Company’s shares on the Canadian Securities Exchange (CSE).  Once the Required Filings are made within 90 days of the date of the FFCTO, such filings will constitute the Company’s application to have the FFCTO revoked.  The Company will issue a further news release when the Required Filings have been made, and it is expected that the Company’s stock will resume trading on the Canadian Securities Exchange at that time.

The FFCTO, among other things, (i) revokes the MCTO in respect of certain officers of the Company, which prohibited those officers from trading in the Company’s securities until after the Company cured its disclosure defaults; and (ii) prohibits any person or company from trading, directly or indirectly, in any security of the Company in the Province of Ontario, and in every other province or territory of Canada in which the Company is a reporting issuer and in which Multilateral Instrument 11-103 – Failure-to-File Cease Trade Orders in Multiple Jurisdictions applies.

A copy of the FFCTO will be posted on the website of the Canadian Securities Administrators at cto-iov.csa-acvm.ca.  The Company will also post a copy of the FFCTO on the Company’s website.

Private Placement Offering Suspended
The Company also wishes to announce that it has voluntarily suspended the anticipated closing of the previously announced private placement offering of up to $2,000,000 of $0.05 Units until the FFCTO is revoked. The Company did not accept any of the subscriptions and did not issue any securities under the private placement.   At this time, the Company continues to evaluate options to preserve shareholder value and provide the Company with the required financial and operational resources required for ongoing operations. During the FFCTO period the Company will continue to update shareholders on the progression of these initiatives.

Additional Management Update to Follow Shortly
Management will be delivering a comprehensive business update to the Company’s shareholders in the coming days, where it will provide further details regarding the Company’s current position and outline plans for moving forward.

About North Bud Farms Inc.
NORTHBUD owns and operates, through its Canadian subsidiary, GrowPros MMP Inc., a licensed cannabis facility in Quebec, Canada. The Company built and owns a state-of-the-art purpose-built cannabis production facility located on 135 acres of agricultural land in Low, Quebec, Canada. The Low, Quebec facility currently has 24,500 sq. ft. of licensed indoor cultivation space; the Company has recently submitted its licence amendment application to Health Canada to add an additional 1,000,000 sq. ft. of outdoor cultivation space.

For more information visit: www.northbud.com

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward- looking statements that include, but are not limited to, the timing of the Company filing the Required Filings. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such risks and uncertainties include, among others, the risk factors included in North Bud Farms Inc.’s final long form prospectus dated August 21, 2018, which is available under the issuer’s SEDAR profile at www.sedar.com.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
North Bud Farms Inc.
Edward Miller
VP, IR & Communications
Office: (855) 628-3420 ext. 3
[email protected] 

CLIENT FEATURE: Eyecarrot Innovations $EYC.ca Creating Faster Brains Through Stronger Eyes $EYPT $KALA

Posted by AGORACOM-JC at 5:54 PM on Tuesday, June 2nd, 2020
http://www.smallcapepicenter.com/eyc%20square.png

EYC: TSX-V

Trusted and used by some of the world’s top professional sports teams, including:

Why Eyecarrot?

  • Eyecarrot Has Already Started Commercializing Its Vision Therapy Platform
  • Company’s Vision Therapy Products Used In:
    • Over 1,500 Practices
    • 20 Countries
  • Flagship “Binovi” Is State-Of-The-Art Platform
    • Measures 14 Key Vision Skills
    • Essential For Maximizing Brain Performance
    • Shipped Over 400 Binovi Units (April 2020)
    • Goal Is 2,500 Binovi Units (End Of 2020)
  • Signed Sports Vision Partnership With Eli Wilson Goaltending
    • World Leader In Goaltending Development
    • 600 Active Goaltending Camp Participants
    • 50,000 Global Aspiring Goaltenders
  • Closed Major Financing In Q1 2020
  • Eyecarrot is now well positioned to further commercialize and capitalize on massive demand for Vision Therapy and Training For Athletes and Education

Serial Entreprenuer and Former Aurora Cannabis CEO, Terry Booth, Joins Eyecarrot as Executive Chairman

  • Mr. Booth was one of the 2 original founders of Aurora Cannabis Inc. In 2013, he personally provided over $3.0 million in start-up capital to the building of a new from the ground up high quality purpose-built medical cannabis production facility in Mountain View County.
  • Appointed CEO in December 2014, he has skillfully raised Aurora from its infancy into one of the world’s largest and fastest growing cannabis companies, valued at $18B at its peak

THE MARKET OPPORTUNITY

  • Vision Therapy captures 3% of a $36B Yearly Vision Market today
  • Vision Therapy will grow by 22% this year and account for 4% of the $39B Yearly Market by year end
  • Sights are set on disrupting the sports performance industry in 2020 while receiving engagement from leaders within the human performance – sport performance industry
  • The size of the sports performance market reached a value of nearly $488.5B in 2018, having grown at a compound annual growth rate (CAGR) of 4.3% since 2014
  • Expected to grow at a CAGR of 5.9% to nearly $614.1B by 2022

WATCH OUR RECENT INTERVIEW

Eyecarrot Innovations is an advertising client of AGORA Internet Relations Corp.

#AI tools could improve fake news detection by analyzing users’ interactions and comments – SPONSOR: Datametrex AI Limited $DM.ca

Posted by AGORACOM-JC at 5:12 PM on Tuesday, June 2nd, 2020

SPONSOR: Datametrex AI Limited (TSX-V: DM) A revenue generating small cap A.I. company that NATO and Canadian Defence are using to fight fake news & social media threats. The company is working with US Government agencies on Covid19 and Coronavirus fake news and disinformation. The company also obtained the rights to import and sell COVID-19 test kits from South Korea – Click here for more info.

AI tools could improve fake news detection by analyzing users’ interactions and comments

  • According to the Pew Research Center, approximately 68% of U.S. adults got their news from social media in 2018 — which is worrisome, considering misinformation about the pandemic, for instance, continues to go viral
  • Companies from Facebook and Twitter to Google are pursuing automated detection solutions, but fake news remains a moving target, owing to its topical and stylistic diversity

By: Kyle Wiggers

In a paper published on the preprint server Arxiv.org, researchers affiliated with Microsoft and Arizona State University propose an approach to detecting fake news that leverages a technique called weak social supervision. They say that by enabling the training of fake news-detecting AI even in scenarios where labeled examples aren’t available, weak social supervision opens the door to exploring how aspects of user interactions indicate that news might be misleading.

According to the Pew Research Center, approximately 68% of U.S. adults got their news from social media in 2018 — which is worrisome, considering misinformation about the pandemic, for instance, continues to go viral. Companies from Facebook and Twitter to Google are pursuing automated detection solutions, but fake news remains a moving target, owing to its topical and stylistic diversity.

Building on a study published in April, the coauthors of this latest work suggest that weak supervision — where noisy or imprecise sources provide data labeling signals — could improve fake news detection accuracy without requiring fine-tuning. To this end, they built a framework dubbed Tri-relationship for Fake News (TiFN) that models social media users and their connections as an “interaction network” to detect fake news.

Interaction networks describe the relationships between entities like publishers, news stories, and users. Given an interaction network, TiFN aims to embed different types of entities, based on the observation that people tend to interact with like-minded friends. In making its predictions, the framework also accounts for the fact that connected users are more likely to share similar interests in news pieces, that publishers with a high degree of political bias are more likely to publish fake news, and that users with low credibility are more likely to spread fake news.VB Transform 2020 Online – July 15-17. Join leading AI executives: Register for the free livestream.

To test whether TiFN’s weak social supervision could help to detect fake news effectively, the team validated it against a Politifact data set containing 120 true news pieces and 120 verifiably fake pieces shared among 23,865 users. Versus baseline detectors that consider only news content and some social interactions, the researchers report that TiFN achieved between 75% to 87% accuracy, even with a limited amount of weak social supervision (within 12 hours after the news was published).

In another experiment — involving a separate custom framework called Defend — the researchers sought to use news sentences and user comments explaining why a piece of news is fake as a weak supervision signal. Tested on a second Politifact data set consisting of 145 true news and 270 fake news pieces with 89,999 comments from 68,523 users on Twitter, they say Defend achieved 90% accuracy.

“[W]ith the help of weak social supervision from publisher-bias and user-credibility, the detection performance is better than those without utilizing weak social supervision. We [also] observe that when we eliminate [the] news content component, user comment component, or the co-attention for news contents and user comments, the performances are reduced. [This] indicates capturing the semantic relations between the weak social supervision from user comments and news contents is important,” wrote the researchers. “[W]e can see [that] within a certain range more weak social supervision leads to a larger performance increase, which shows the benefit of using weak social supervision.”

Source: https://venturebeat.com/2020/06/01/ai-tools-could-improve-fake-news-detection-by-analyzing-users-interactions-and-comments/

New Age Metals $NAM.ca River Valley Drilling Continues to Intersect and Expand #Palladium Mineralization at the Pine Zone $WG.ca $XTM.ca $WM.ca $PDL.ca $GLEN #PGM

Posted by AGORACOM-JC at 9:13 AM on Tuesday, June 2nd, 2020
  • Palladium mineralization is still open to expansion by drilling to the east, particularly testing a strong IP chargeability high located about 400 metres along strike, and also by drilling down-dip to the south
  • Hole PZ-20-04 intersected 1101 ppb Pd+Pt+Au (1.250 g/t PdEq) over 12 metres from 50 metres downhole, including 1361 ppb Pd+Pt+Au over 8 metres in the Pine Zone; and
  • Hole PZ-20-01 intersects 1287 ppb Pd+Pt+Au (1.477 g/t PdEq) over 3 metres from 168 metres downhole in the Pine Zone

June 2nd, 2020 – Rockport, Canada – New Age Metals Inc. (TSXV:NAM); (OTC:NMTLF); (FSE:P7J) – The Company is pleased to announce new results from the 2020 Phase 1 exploration drilling program at its 100% owned River Valley Palladium Project. This district-scale land package and large mineral resource is located near the City of Sudbury, Ontario,
and its world-class mining and processing facilities.

Chairman and CEO Harry Barr stated; “Phase 1 of the 2020 drill program was successful in extending the known limits of the Pine Zone Palladium mineralization 50 metres up-dip to the north and 50 metres along strike to the east. The Palladium mineralization is still open to expansion by drilling to the east, particularly testing a strong IP chargeability high located about 400 metres along strike, and also by drilling down-dip to the south (see Figure 1). The 2020 drilling was also successful at broadly establishing the presence of Palladium mineralization at the connection of the Pine Zone to the Dana North Zone.”

This release describes results from 1,685.5 metres of drilling in 8 holes completed in Q2 2020 on the Pine Zone-Dana North Zone area of the multi-million-ounce River Valley Palladium Project. The objectives of the drill program were threefold: 1) expand the limits of the Pine Zone Palladium mineralization; 2) investigate possible connection of the Pine Zone to the Dana North Zone at depth; and 3) test Palladium mineralization continuity within the 2019 Block Model.
The drill program was successful in extending the Pine Zone mineralization up-dip to the north and along strike to the east, thereby demonstrating opportunity to further expand the Mineral Resources in support of a Prefeasibility Study in 2021-2022.

The Pine Zone was discovered by drilling an IP chargeability high in 2015-2016, in the footwall to the main River Valley deposit at the Dana North Zone, at the north end of the Property and under the main access road. Seven holes were drilled into the Pine Zone-T3 area in 2015-2016 and 14 in 2017 plus the 5 in 2020 for a total of 26 holes. Before 2015, seven holes had been drilled through the Dana North Zone and into the Pine Zone prior to recognition of the latter as a separate, differently oriented zone.

2020 Palladium Highlights

Highlights of the Phase 1 2020 drill program are as follows:

– Hole PZ-20-04 intersected 1101 ppb Pd+Pt+Au (1.250 g/t PdEq) over 12 metres from 50 metres downhole, including 1361 ppb Pd+Pt+Au over 8 metres in the Pine Zone; and

– Hole PZ-20-01 intersects 1287 ppb Pd+Pt+Au (1.477 g/t PdEq) over 3 metres from 168 metres downhole in the Pine Zone

Palladium Results

The details of the Phase 1 2020 drill program are presented in Tables 1-2 and Figure 1.
Holes PZ-20-02 and PZ-20-04, -05 and -06 were drilled to expand the Palladium mineralization beyond the 2019 Mineral Resources at the Pine Zone. Hole PZ-20-02 targeted an IP chargeability high and intersected 0.597 g/t PdEq from 125 metres downhole, which expands the mineralization 50 metres along strike to the east from the Mineral Resource Block Model. Holes PZ-20-04, -05 and -06 were drilled to expand the Palladium mineralization up-dip to the north, by 10 metres,
50 metres and 100 metres, respectively. Hole PZ-20-04 targeted an IP chargeability high and intersected 12 metres grading 1.250 g/t PdEq from only 50 metres downhole, including
8 metres at 1.542 g/t PdEq
, and 5 metres grading 0.499 g/t PdEq from 66 metres downhole.
Hole PZ-20-05 intersected 3 metres grading 0.857 g/t PdEq from only 50 metres downhole.
This intersection appears to be slightly more copper rich (Table 2). Hole PZ-20-06 lacked significant assay results but did intersect the breccia unit, the favourable host rock for the Palladium mineralization at River Valley.

Holes T3-20-01, T3-20-02 and PZ-20-03 were drilled to test for the presence of Palladium mineralization where the Pine Zone may be connected at depth to the main River Valley Palladium deposit at the Dana North Zone. Palladium mineralization was intersected in all three holes:
1) Hole T3-20-01 intersected 17 metres grading 0.744 g/t PdEq from 248 metres downhole;
2) T3-20-02 intersected 17 metres of 0.622 g/t PdEq from 318 metres downhole; and 3) PZ-20-03 intersected 0.412 g/t PdEq from 197 metres downhole.

Hole PZ-20-01 was designed to test Palladium grade continuity within the 2019 Mineral Resource Model. PZ-20-01 was collared 50 metres from the nearest previously drilled hole and intersected 3 metres grading 1.477 g/t PdEq from 168 metres downhole. This intersection lies within the Block Model volume of the 2019 mineral resource.


Click Image To View Full Size

* Collar coordinates are UTM NAD83 Zone 17N


Click Image To View Full Size

Notes: 1000 ppb = 1 gram/tonne

The lengths reported are core lengths, but should approximate true widths

nsa = no significant assays

PdEq g/t = Pd g/t + (Pt g/t x 0.89) + (Au g/t x 1.20) + (Cu% x 1.34) + (Ni% x 2.55) + (Co% x 9.01)

For PdEq calculation details, see 2019 Technical Report, “Updated Mineral Resource Estimate and Preliminary Economic Assessment of the River Valley Project”, by P&E Mining Consultants Inc. and DRA Americas Inc.


Click Image To View Full Size

Figure 1. Location of 2020 Phase 1 drill holes (labelled) and previously drilled holes plotted on an inverted IP chargeability image (coloured) and 3-D wireframe model of the Dana North Zone and Pine Zone (covered), River Valley Palladium Project near Sudbury (Ontario, Canada). Note from the inset map that the River Valley Palladium Project is located 60 linear km ENE of the City of Sudbury.

Discussion

The Palladium mineralization at the Pine Zone remains open to expansion by drilling to the east, particularly testing a strong IP chargeability high located about 400 metres along strike, and also by drilling down-dip to the south. Palladium mineralization was also broadly established at the connection of the Pine Zone to the Dana North Zone.

The results of the 2020 Phase 1 drilling bring the cumulative total number of holes intersecting the Pine Zone to 33. The number of Palladium mineralized intersections within the Pine Zone now totals 41, over an area measuring up to 250 metres along strike and 550 metres down-dip.
Note again that the Pine Zone remains open down-dip and particularly to the east, where the most tantalizing IP chargeability high is located.

Assay Procedures & QA/QC

The 2020 Phase 1 drilling was completed by Jacob & Samuel Drilling Ltd. of Sudbury, Ontario under the supervision of NAM geologists. The drill core samples were sent to the SGS Canada Inc. Laboratory in Lakefield, Ontario for sample preparation and assay analyses. The preparation involved crushing of 3 kg of each sample to 90% passing 2 mm, and then pulverizing 0.5 kg to 85% passing 75 um. Palladium, Platinum and Gold were assayed by fire assay with ICP-AES finish (GE-FAI313). Copper, Nickel and 32 additional metals were assayed by two acid digestion and ICP-OES finish (GE-ICP14B). Blanks and blind certified standard samples were submitted at regular intervals for assay with the core samples as part of NAM’s rigorous Quality Assurance/Quality Control program.

Next Steps

NAM is considering its next steps in Palladium exploration and project development at River Valley in 2020. The next steps include any one or a combination of the following activities:

– Analyze significant Palladium core intersections in the Pine Zone for Rhodium;

– Update the 3-D geological modelling of the Pine Zone;

– Carry out further environmental baseline studies (including an archaeological survey);

– Complete Phase 2 drilling, particularly at the priority footwall IP chargeability high,

the Pine Zone-Dana North Zone connection, and down-dip;

– Conduct borehole-IP surveys for off-hole anomalies outside the known resource; and

– Undertake Phase 2 metallurgical studies

The purpose of these activities would be to advance the River Valley Palladium Project and support the Prefeasibility study planned for 2021-22.

About the River Valley Palladium Project

The details of the updated Mineral Resource Estimate (MRE) and Preliminary Economic Assessment (PEA) were announced in the press release dated August 9, 2019 and are described on NAM’s website. The pit constrained Updated Mineral Resource Estimate formed the basis of the PEA. At a cut-off grade of 0.35 g/t PdEq, the Updated Mineral Resource Estimate contains 2.867 Moz PdEq in the Measured plus Indicated classifications and 1.059 Moz PdEq in the Inferred classification. The PEA is a preliminary report, but it demonstrates that there are potentially positive economics for a large-scale mining open pit operation, with 14 years of Palladium production. Refer to the NAM website (www.newagemetals.com) for details.

About NAM

New Age Metals is a junior mineral exploration and development company focused on the discovery, exploration and development of green metal projects in North America.
The Company has two divisions; a Platinum Group Metals division and a Lithium/Rare Element division. The PGM division includes the 100% owned River Valley Project, one of North America’s largest undeveloped Platinum Group Metals Projects, situated 100 km from Sudbury, Ontario and the Genesis PGM Project in Alaska. The Lithium division is the largest mineral claim holder in the Winnipeg River Pegmatite Field where the Company is exploring for hard rock lithium and various rare elements such as tantalum and rubidium. Our philosophy is to be a project generator with the objective of optioning our projects with major and junior mining companies through to production. New Age Metals is a junior resource company on the TSX Venture Exchange, trading symbol NAM, OTCQB: NMTLF; FSE: P7J with 137,347,966 shares issued to date.

Investors are invited to visit the New Age Metals website at www.newagemetals.com where they can review the company and its corporate activities. Any questions or comments can be directed to [email protected] or Harry Barr at [email protected] or Cody Hunt at [email protected] or call 613 659 2773.

Opt-in List

If you have not done so already, we encourage you to sign up on our website (www.newagemetals.com) to receive our updated news.

Qualified Person

The contents contained herein that relate to Exploration Results or Mineral Resources is based on information compiled, reviewed or prepared by Bill Stone, P.Geo., a consulting geoscientist for New Age Metals. Dr. Stone is the Qualified Person as defined by National Instrument 43-101 and has reviewed and approved the technical content of this news release.

On behalf of the Board of Directors

Harry Barr”

Harry G. Barr

Chairman and CEO

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward Looking Statements: This release contains forward-looking statements that involve risks and uncertainties. These statements may differ materially from actual future events or results and are based on current expectations or beliefs. For this purpose, statements of historical fact may be deemed to be forward-looking statements. In addition, forward-looking statements include statements in which the Company uses words such as “continue”, “efforts”, “expect”, “believe”, “anticipate”, “confident”, “intend”, “strategy”, “plan”, “will”, “estimate”, “project”, “goal”, “target”, “prospects”, “optimistic” or similar expressions. These statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others, the Company’s ability and continuation of efforts to timely and completely make available adequate current public information, additional or different regulatory and legal requirements and restrictions that may be imposed, and other factors as may be discussed in the documents filed by the Company on SEDAR (www.sedar.com), including the most recent reports that identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements. The Company does not undertake any obligation to review or confirm analysts’ expectations or estimates or to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Investors should not place undue reliance on forward-looking statements.

Mota Ventures $MOTA.ca Closes $20,000,000 Acquisition of European Pharmaceutical Manufacturer of Natural Psilocybin Extracts $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 7:41 AM on Tuesday, June 2nd, 2020
  • The market for psychedelic derived medicines and therapies is estimated to be as high as USD$100 Billion

VANCOUVER, BC / June 2, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTC PINK:PEMTF) (the “Company“) a leading ecommerce provider of CBD products to consumers in the United States and Europe, is pleased to announce the completion of its’ Cdn$20,000,000 acquisition (the “Transaction“) of all of the outstanding share capital of Verrian Ontario Ltd. (“Verrian“) effective June 1, 2020. Verrian is an established and well advanced European psychedelic medicine company that is focused on delivering and developing products related to addiction reduction, with a focus on alcohol and opiates.

Ryan Hoggan, CEO of the Company stated, “The massive shift towards psychedelic derived medicines is no longer in doubt and this acquisition sends a strong signal to the market that Mota Ventures intends to be a serious participant this coming decade. Unlike some companies that use psychedelics as a marketing term, this acquisition of Verrian brings Mota market ready products, world renowned addiction medicine experts, R&D facilities and a 110,000 square foot facility to make it happen. In my opinion this is the most complete psychedelic asset on the market, and therefore should immediately make Mota a market leader in the space.”

Hoggan further added, “In 2020, we have proven our e-commerce ability to acquire tens of thousands of customers and generate millions of dollars in monthly revenues from CBD sales. We intend to bring that same market expertise to bear with our psychedelics business in 2020 and far beyond.”

ACQUISTION PROVIDES MOTA WITH IMMEDIATE ENTRY INTO FAST GROWING $100 BILLION PSYCHEDELICS INDUSTRY

The market for psychedelic derived medicines and therapies is estimated to be as high as USD$100 Billion*. Over the past decade, growing societal awareness and acceptance of mental disorders and addiction as real diseases has accelerated the push for new and innovative treatments using psychedelics, including psilocybin.

As a result, psychedelic research published back in the 50s and 60s has resurfaced and once again highlighted their curative properties. Moreover, the recent legalization of Cannabis in Canada, as well as, across 33 US states for medicinal purposes, has significantly mitigated any stigma, leading to accelerated interest and investment in the psychedelics industry.

Verrian has already developed two psilocybin products that are natural psilocybin extracts, from organically cultivated mushrooms, combined with metabolism enhancing natural herbs. This is only the beginning with further products in various stages of development.

ESTABLISHED EUROPEAN PSYCHEDELIC MEDICINE COMPANY

Verrian owns and operates a 110,000 square foot pharmaceutical manufacturing facility in Radebuel, Germany. Operations within this full suite pharmaceutical manufacturing site include analytical laboratory and finished dose manufacturing, which exceed all international quality standards. The facility and equipment of Verrian have been independently appraised at Cdn$10,600,000 and include an analytical laboratory and full pharmaceutical manufacturing suite.

Verrian operates three distinct business segments:

  • Pharmaceutical Manufacturing – A portfolio of medical & wellness products
  • Phyto API – API creation from medical plants
  • Analytical Testing – European Medicine Agency Standards

PRODUCTS FOCUSED ON OPIATE ADDICTION REDUCTION

Verrian’s singular focus is rewiring the mind to overcome addiction through natural medicine. Specifically, the micro dosing of psilocybin demonstrates potential to remove the dopamine reward of addictive substances, potentially diminishing the desire for addictive substances, thereby reducing or eliminating the need for the addictive substance.

To date Verrian has developed two psilocybin products: PSI GEN and PSI GEN+. These Psilocybin products are focused on opiate addiction reduction. As natural psilocybin extracts, from organically cultivated mushrooms, combined with metabolism enhancing natural herbs, they are ideal for individuals commencing micro-dosing and capable of being combined with additional anti-addiction therapies.

All of Verrian’s compounds are derived from organic, glyphosate free naturally occurring plants, grown specifically for its own purposes.

GOALS AND VISION

In addition to the facility and equipment outlined above, Verrian has invested approximately Cdn$2,400,000 in clinical trial design and development of proprietary formulations for its psilocybin trademarked PSI-GEN products, and cannabis products, including trademarked CBDaily and CBNight.

Verrian’s world renowned addiction medicine experts are moving ahead to develop new potential treatments for therapy, with rigorous clinical research. Once EU GMP and narcotics handling recertification are secured, capabilities will extend to: specialty pharmaceutical formulations; and psilocybin refinement and production for micro dosing.

In consideration for the acquisition of all of the outstanding share capital of Verrian, the Company has issued 54,347,826 common shares (the “Consideration Shares“) to the existing shareholders of Verrian at a deemed price of $0.368 per Consideration Share. 50,543,478 of the Consideration Shares are subject to terms of a thirty-six month time release pooling arrangement, during which time they may not be transferred, assigned, pledged or otherwise traded. The Consideration Shares will be released from the pooling arrangement in tranches, of which ten-percent will be released after four months, fifteen percent after six months, and the balance in five equal tranches every six months thereafter. In addition to the Consideration Shares, upon closing of the Transaction, the Company has arranged for repayment of $150,000 of existing shareholder loans of Verrian, and will arrange for repayment of the balance of $950,000 within sixty days of closing.

The Company is at arms-length from Verrian, and each of its shareholders. The Transaction does not constitute a fundamental change for the Company, nor has it resulted in a change of control of the Company, within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange. In connection with completion of the Transaction, the Company has paid a finders’ fee of 5,434,783 common shares to certain arms’-length parties who have assisted in facilitating the Transaction. The Company has also paid an administrative fee of 1,086,957 common shares of the Company to a consultant who assisted with the Transaction.

We encourage shareholders and prospective investors to visit the Company’s AGORACOM Discussion Forum, a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders.

About Mota Ventures Corp.

Mota Ventures is an established natural health products company focused in the CBD and psychedelic medicine sectors. Through its powerful eCommerce business, Mota is a leading is a direct-to-consumer provider of a wide range of natural health products throughout the United States and Europe. In the United States, the Company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the United States through its Nature’s Exclusive brand. Within Europe, its Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom.

Through its German-based Verrian operation, Mota is researching and testing the efficacy and application of natural psilocybin products for the treatment of opioid and other life altering addictions. Mota is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD and other natural health products.

ON BEHALF OF THE BOARD OF DIRECTORS
MOTA VENTURES CORP.

Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Empower $CBDT.ca #Covid19 Testing Expands to Phase Three and May 2020 Patient Visits Exceed Expectations $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 7:12 AM on Tuesday, June 2nd, 2020
  • Empower has commenced phase three of COVID-19 testing with a successful pilot of business employee testing
  • Outperforms expected May 2020 patient volume with over 2,300 physician-patient consultations

VANCOUVER BC / June 2nd, 2020 / EMPOWER CLINICS INC. (CSE:CBDT) (OTCQB:EPWCF) (Frankfurt:8EC) (“Empower” or the “Company“), a vertically integrated life sciences company, is pleased to announce that Empower has successfully conducted COVID-19 antibody business employee testing, solidifying the importance of phase three of the testing program. In addition, the Company conducted 2,302 physician-patient consultations setting a new milestone in patient volume for the month of May.

“We established a four-phase approach to the roll-out of COVID-19 testing, ensuring operational excellence throughout the launch”, said Steven McAuley, Chairman & CEO of Empower. “A positive patient experience is imperative to our success, and therefore, establishing precise disciplined pilot programs that are measured, with quantifiable metrics, insure we can scale effectively.”

In an effort to bolster the the Sun Valley Health division, we have hired three new call centre specialists, two new clinic technicians and a full-time phlebotomist… a trained specialist in drawing blood samples for testing.

“During this time of crisis, our team continues to demonstrate patient advocacy and grows stronger in the face of challenges.” said Dustin Klein, SVP Business Development “We continue to see a record number of patients each week, and with the new diversified health and wellness services being offered, we are fortunate to be able to hire new staff.”

Phase One Testing in clinics in Arizona, utilizing a patient blood draw by clinic phlebotomists, then samples are sent to our laboratory test partner for analysis, with test results expected within 48 hours. This program is active and appointment rates are expanding rapidly.

Phase Two Offering a Rapid COVID-19 antibody test with results in 1-15 minutes. The service will be offered in-clinics using a drive-up service, conducted by Company clinic staff. In addition, an outbound door-step service, to support a variety of consumer, patient and community needs will be offered using certified mobile technicians. The online portal is open to book appointments.

Phase Three Business Employee Testing (BET) programs, offering Rapid COVID-19 testing to businesses on a one-time basis, repeat basis and/or subscription basis, to assist businesses to get back to work safely, has been offered. The phase three pilot programs have successfully been delivered establishing a new revenue stream for the Company.

Phase Four U.S. nationwide roll-out, offering all phases of Company services, that can be accessed online at Company websites and call centers, to purchase Rapid COVID-19 test kits. The Company anticipates phase four services to may commence in Q3 2020.

ABOUT EMPOWER

Empower is a vertically integrated health & wellness company with a network of corporate and franchised health & wellness clinics in the U.S. The Company is a leading multi-state operator of a network of physician-staffed wellness clinics, focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has launched Dosed Wellness Ltd. to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Steven McAuley

Chairman & CEO

[email protected]

604-789-2146

Investors: Dustin Klein

SVP, Business Development

[email protected]

720-352-1398

For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws.All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding: the Company’s expected timing of filing of its Annual Filings, the Company’s intention to create psilocybin and psychedelics divisions, that market research on advancements in psilocybin and psychedelics in North America and globally will create greater shareholder value, the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond; the ability of the Company to complete or execute phases One, Two, Three or Four of COVID-19 test programs, and Psychedelic substances remain illegal in most countries, so please reference your local laws in relation to medical or recreational use. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.